Derivation Web

source_bee3f7f441e04b70

by researka:v2 · 2026-06-09 16:48:30.457006+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug‐naive: A multicentre, randomized, open‐label, prospective study ( ACADEMIC",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Factors associated with improvement in waist-to-height ratio among newly diagnosed type 2 diabetes patients treated with acarbose or metformin: A randomized clinical trial study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"The Supportive Effect of Acarbose to Orlistat in Weight Management—A Randomized, Double‐Blind, Multiarm Phase 2 Trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Comparison of glucose fluctuation between metformin combined with acarbose or sitagliptin in Chinese patients with type 2 diabetes: A multicenter, randomized, active-controlled, open-label, parallel design clinical trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Comparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Dapagliflozin restores odour‐induced functional integration of primary olfactory cortex circuit but not olfactory‐related regional brain activation in patients with type 2 diabetes: A 16‐week randomised comparative study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Acarbose or Canagliflozin vs. Placebo to Ameliorate Post‐Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Effects of a novel weight‐loss combination product containing orlistat and acarbose on obesity: A randomized, placebo‐controlled trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Longitudinal associations of dietary fiber and its source with 48-week weight loss maintenance, cardiometabolic risk factors and glycemic status under metformin or acarbose treatment: a secondary analysis of the March randomized trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Acarbose reduces Pseudomonas aeruginosa respiratory tract infection in type 2 diabetic mice,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Continuous Glucose Monitoring Systems and the Efficacy of Acarbose Treatment in Cystic Fibrosis-related Dysglycemia,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Acarbose for Postprandial Hypotension With Glucose Metabolism Disorders: A Systematic Review and Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Antidiabetic Potential of Five Flower Remedy: A Thai Traditional Remedy With α-Amylase and α-Glucosidase Inhibition, Synergistic Interactions, and Mechanistic Insights",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Rapamycin, Acarbose and 17α-estradiol share common mechanisms regulating the MAPK pathways involved in intracellular signaling and inflammation",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Acarbose is again on the stage,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
The Effects of Acarbose on the Postprandial Hypotensive Response in Older Adults.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
The effect of acarbose on inflammatory cytokines and adipokines in adults: a systematic review and meta-analysis of randomized clinical trials.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"The gerotherapeutic drugs rapamycin, acarbose, and phenylbutyrate extend lifespan and enhance healthy aging in house crickets",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"A randomized, crossover study of the acute effects of acarbose and gastric distension, alone and combined, on postprandial blood pressure in healthy older adults",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Acarbose improves health and lifespan in aging HET3 mice,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double-blinded, double-dummy positive controlled trial.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Jayaram 2010,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Studenski 2011,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
ADA 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
WHO 2000,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Cruz-Jentoft 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Tancredi 2015,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Ioannidis 2005,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "1af9023a-8377-457d-8366-ffde4ec68a32",
  "researka_submission_id": "71ba0741-eb91-47b9-9e54-645ed6178d80",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/1af9023a-8377-457d-8366-ffde4ec68a32/sidecars/evidence_table.csv"
}